BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/22 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Downgrade Market perform (from market outperform) -11% $25.84
Schimmer also reduced his target to high-$20s from high-$30s after a survey of 43 multiple sclerosis specialists showed mixed results for the ramp and market penetration of Acorda's Ampyra dalfampridine to improve walking ability in MS patients. Schimmer downgraded until there is "greater confidence" of the product's market penetration. Acorda launched the sustained-release formulation of 4-aminopyridine in March.
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Piper Jaffray Edward Tenthoff Downgrade...

Read the full 659 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >